

Direct Dial: (908) 298-7354  
Direct Fax: (908) 298-7303  
Email: susan.wolf@spcorp.com



May 30, 2007

**Richard Wood**  
Chair, Keep Antibiotics Working Coalition  
P.O. Box 14590  
Chicago, Illinois

Dear Mr. Wood:

Our CEO directed your letter to Christopher Ragland at Intervet to me in my role as Vice President, Corporate Governance of Schering-Plough. We have already been contacted by Schering-Plough shareholders who are interested in your work, including Margaret Weber representing the Adrian Dominican Sisters, and listed it as a matter for study.

At this time, our proposed combination with the Organon BioSciences companies including Intervet has not yet received regulatory approval, including approvals from antitrust regulators around the world. As a result, we are not yet analyzing or commenting on issues surrounding the Intervet products.

We know that there are strong feelings on all sides of the antibiotics issue discussed in your letter and that there are many scientific studies that are pertinent to understanding the issue. We appreciate your making sure that we are aware of the studies that you find most relevant. Consistent with our "Listen and Lean" and "Continuously Improve" leader behaviors, we are always interested in conducting study and holding dialogues with parties having various views on important issues to help us understand all perspectives.

After our transaction has been approved and closed, Peter Gallagher, our Director, Strategic Affairs, will keep in touch to let you know of our work in studying this issue, and to invite you to dialogue with us on this issue at the appropriate time. We appreciate

your interest in Schering-Plough and your taking time to copy our CEO on your correspondence with Intervet.

Sincerely,



Susan Ellen Wolf  
Vice President-Corporate Governance

cc: Peter Gallagher  
Christopher Ragland  
Margaret Weber